CSO C. David Pauza, Ph.D. Presents on Cell and Gene Therapy for HIV Disease

Chief Science Officer C. David Pauza, Ph.D. Presents At the Intersection of Genetic Medicine and Immunotherapy: Clinical Experience with a Cell and Gene Therapy for HIV Disease

ROCKVILLE, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) -- AmericanGene Technologies(AGT)a cutting-edge cell and gene therapy company in Rockville, Maryland announced today that CEO Jeff Galvin will present at the annual Cell & Gene Meeting on the Mesa. The meeting will be held virtually October 12-16. Galvins presentation will highlight the company's technology, including AGT103-T, a therapeutic intended to cure HIV, which is scheduled to begin Phase 1 clinical trials this month.

Specifics of AGTs clinical trial can be found at https://clinicaltrials.gov/ct2/show/NCT04561258, and details of the HIV therapy intended to cure the disease are on the AGT web site.

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a five-day virtual conference featuring more than 120 presentations from the leading public and private companies. These presentations will highlight the most exciting technical and clinical achievements from the past 12 months in cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies. The meeting also includes over 100 panelists and features speakers taking part in 20 in-depth sessions covering all aspects of cell and gene therapy commercialization.

The following are specific details regarding AmericanGene Technologies presentation at the conference:

Please visit http://www.meetingonthemesa.com for full information including registration. Complimentary attendance at this event is available for accredited investors and members of the media. Investors should contact Laura Stringham at lstringham@alliancerm.org and interested media should contact Kaitlyn Dupont at kdupont@alliancerm.org. The event hashtag is #CGMOM20.

About American Gene Technologies (AGT)

AmericanGene Technologies(AGT)is a gene and cell therapy company with a proprietary gene-delivery platform for rapid development of cell and gene therapies. AGTs mission is to transform peoples lives by designing highly effective therapeutics to cure infectious diseases, cancers, and inherited disorders. AGT has received three patents for the technology used to make the AGT103-T cell product and ten patents for its uniqueimmuno-oncology approachto stimulategamma-delta () T cellsto destroy a variety of solid tumors. The company has also developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. AGT's treatment for PKU has been grantedOrphan Drug Designationby the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2021.

More information is available on:

Website - http://www.americangene.comLinkedIn - LinkedInTwitter -@americangeneFacebook -@amerigeneInstagram -@americangenetechnologies

American Gene Technologies Contacts:

C. Neil Lyons, Chief Financial OfficerPhone: (301) 337-2269Email:info@americangene.comwww.americangene.com

Sasha Whitaker, Digital Marketing and CommunicationsPhone: (301) 337-2100Email:swhitaker@americangene.comwww.americangene.com

A video is available at the following link:https://www.globenewswire.com/NewsRoom/AttachmentNg/2623868c-a33f-49c1-bc46-0c114cbd1d83

See the original post here:

American Gene Technologies to Present at 2020 Virtual Cell & Gene Meeting on the Mesa - GlobeNewswire